Cunbo Ma
Research Subjects
Research Interests
Cunbo Ma has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Di Kang
Department of Pharmacology, Jacobio Pharmaceuticals Co., Ltd., Beijing, China
16 shared publications - Yanping Wang
Department of Pharmacology, Jacobio Pharmaceuticals Co., Ltd., Beijing, China
16 shared publications - Yinxiang Wang
Jacobio Pharmaceuticals Group Co., Ltd., Beijing, China
16 shared publications - Chao Bi
Department of Clinical Medicine, Jacobio Pharmaceuticals Co., Ltd., Beijing, China
15 shared publications - Daniel Morgensztern
Washington University School of Medicine, St Louis, MO
15 shared publications - Jing Xiong
Department of Pharmacology, Jacobio Pharmaceuticals Co., Ltd., Beijing, China
15 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Table S3. Representativeness of study participants.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Table S3. Representativeness of study participants.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S9. The anti-tumor activity of JAB-3312 was abrogated by CD8+ T cell depletion. A-B. Tumor growth change (A) and body weight change (B) of MC38 syngeneic model during the treatment. Mean ± SEM was shown.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S9. The anti-tumor activity of JAB-3312 was abrogated by CD8+ T cell depletion. A-B. Tumor growth change (A) and body weight change (B) of MC38 syngeneic model during the treatment. Mean ± SEM was shown.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S2. The combination of JAB-3312 and glecirasib can enhance the inhibitory effect on the growth of KRASG12C mutant tumors in vitro and in vivo. A. Proliferation inhibition of SW837 human colon cancer cells by JAB-3312, glecirasib, or their combination. B-E. The tumor volume change of SW837 (B), MIA PaCa-2 (C), CR6243 (D), and CR6256 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean tumor volumes ± SEM were shown.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S2. The combination of JAB-3312 and glecirasib can enhance the inhibitory effect on the growth of KRASG12C mutant tumors in vitro and in vivo. A. Proliferation inhibition of SW837 human colon cancer cells by JAB-3312, glecirasib, or their combination. B-E. The tumor volume change of SW837 (B), MIA PaCa-2 (C), CR6243 (D), and CR6256 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean tumor volumes ± SEM were shown.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S7. Body weight change of EMT6 syngeneic model during the treatment. Mean ± SEM was shown.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S7. Body weight change of EMT6 syngeneic model during the treatment. Mean ± SEM was shown.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S5. JAB-3312 in combination with MEK inhibitor synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of SW620 human colon cancer cells by JAB-3312, MEKi, or their combination. C-E. The body weight change of SW620 (C), CR1554 (D), and CR3262 (E) xenograft models during the treatment of JAB-3312, MEKi, and the combination. Mean ± SEM was shown.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S5. JAB-3312 in combination with MEK inhibitor synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of SW620 human colon cancer cells by JAB-3312, MEKi, or their combination. C-E. The body weight change of SW620 (C), CR1554 (D), and CR3262 (E) xenograft models during the treatment of JAB-3312, MEKi, and the combination. Mean ± SEM was shown.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S3. Body weight change of KRASG12C mutant tumors. A-E. Body weight change of SW837 (A), MIA PaCa-2 (B), CR6243 (C), CR6256 (D), and LU6405 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean ± SEM was shown.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S3. Body weight change of KRASG12C mutant tumors. A-E. Body weight change of SW837 (A), MIA PaCa-2 (B), CR6243 (C), CR6256 (D), and LU6405 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean ± SEM was shown.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S10. CT images of representative clinical cases over the course of treatment. A. Images of the target legions (nodules in the lower lobe of the right lung and the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. B. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. C. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. D. Images of the target legion (intra-abdominal nodule) over time in a patient with KRAS G12V mutant ovarian serous carcinoma who received JAB-3312 and binimetinib combination therapy. E. Images of the target legion (left abdominal wall nodule) over time in a patient with ESCC who received JAB-3312 and pembrolizumab combination therapy.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S10. CT images of representative clinical cases over the course of treatment. A. Images of the target legions (nodules in the lower lobe of the right lung and the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. B. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. C. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. D. Images of the target legion (intra-abdominal nodule) over time in a patient with KRAS G12V mutant ovarian serous carcinoma who received JAB-3312 and binimetinib combination therapy. E. Images of the target legion (left abdominal wall nodule) over time in a patient with ESCC who received JAB-3312 and pembrolizumab combination therapy.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S8. Representative flow cytometry gating strategy. A-C. Flow cytometry gating strategy for CD4+ and CD8+ T cells (A), IFNγ+ CD8+ T cells (B), and Macrophages (C).
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S8. Representative flow cytometry gating strategy. A-C. Flow cytometry gating strategy for CD4+ and CD8+ T cells (A), IFNγ+ CD8+ T cells (B), and Macrophages (C).
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S6. The combination of JAB-3312 and EGFR inhibitor osimertinib synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of NCI-H1975 (A) and NCI-H1975-C797S (B) human lung cancer cells by JAB-3312, osimertinib, or their combination. C-D. The body weight change of NCI-H1975 (C) and LUN#2355-214 (D) xenograft models during the treatment of JAB-3312, osimertinib, and the two-drug combination. Mean ± SEM was shown.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S6. The combination of JAB-3312 and EGFR inhibitor osimertinib synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of NCI-H1975 (A) and NCI-H1975-C797S (B) human lung cancer cells by JAB-3312, osimertinib, or their combination. C-D. The body weight change of NCI-H1975 (C) and LUN#2355-214 (D) xenograft models during the treatment of JAB-3312, osimertinib, and the two-drug combination. Mean ± SEM was shown.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S1. RMC-4550 was synthesized in house. A. The chemical structure of RMC-4550. B. NMR spectrum of RMC-4550. C. HPLC spectrum of RMC-4550.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Supplementary Figure S1. RMC-4550 was synthesized in house. A. The chemical structure of RMC-4550. B. NMR spectrum of RMC-4550. C. HPLC spectrum of RMC-4550.